Bioprocess Online for bioanalytics, biopurification, bioproduction

Unlocking Method Insights For Novel Engineered AAV Capsids

Microfluidic platforms, such as labchip, are widely used for assessing wild type capsids. Now, engineered capsids are challenging these established workflows.

More Featured Editorial

EDITOR'S DESK

Unlocking The Pharmacological Potential Of Antibodies
Abalone Bio's CEO and co-founder, Richard Yu, Ph.D., explains the company's Functional Antibody Selection Technology (FAST) platform and its approach to developing a pipeline of G protein-coupled receptor (GPCR) mAbs.

Tech Transfer 2025 – A High-Stakes Game Of Trust

Trust us. You'll want to read this editorial from Chief Editor Louis Garguilo, who was (gently) reminded he hadn't visited the subject of tech transfer in a while. He answers the questions both sponsors and CDMOs ask to gain the trust to make a tech transfer work for both sides.

How Lumen Is Putting The "Farm" In Biopharma

Lumen Bioscience's SVP of production and development, Craig Behnke, Ph.D., explains how the company is cutting costs and rethinking upstream manufacturing with its algae-based production platform.

The Safety Potential Of Conditionally Active Biologics

Conditionally active biologics (CABs) are an emerging class of therapies that can reduce off-target toxicity in the clinic, and they were a topic of conversation at the 2025 BIO International Convention.

CDMOs Should Stop Stringing Biotechs Along

Biotechs, first working closely with a CDMO’s sales manager, experience subsequent and sudden rejections of their projects. Did some of you just wince? If so, that might be because we are again hearing of a problem with sudden rejections after protracted discussions and even site visits. Part two on what is one of the biggest problems for outsourcing today.

GUEST COLUMNISTS

Sanofi's Digitalization Road Trip Shifts Into High Gear
The company's head of manufacturing discusses their latest investments in AI and automation, plus offers tips on how any company can start adopting advanced technology.
Why Pharmaceutical And Medical Device Risks Must Be Analyzed By Their Risk Mechanisms
Current risk analysis methods focus on the possibility and severity of bad events instead of focusing directly on analyzing and improving the performance of systems and processes producing the bad events.
NanoCell's Moonshot Aims To Unlock In Vivo Cell Therapy
If the science holds, the implications include substantial cost reduction and putting engineered T cell therapies within reach of patients anywhere in the world.
The Regulatory Imperative To Improve Environmental And Sustainability Stewardship In Biopharma
As the industry faces increasing pressure to align with environmental, social, and governance (ESG) standards, companies must evaluate how to integrate supply chain management with these initiatives to drive sustainability and mitigate risks.
How You And Your CDMO Should Leverage Contamination Control Strategies For Competitive Advantage
It is no longer sufficient to just meet compliance requirements; a proactive, risk-based approach to contamination control is now a differentiating factor that enhances operational efficiency and more. For biotech companies evaluating CDMOs, this shift is critical.
Leveraging AI And Data Science For Biologics Characterization
Modern analytical tools produce more data than we know what do with. Artificial intelligence helps condense, interpret, and utilize what's most meaningful.
Operating And Maintaining Pharmaceutical Gas Distribution Systems
Drug manufacturers face stringent requirements when using gas that comes into direct contact with the product. This guide discusses operation, maintenance, and monitoring of gas systems.
August 2025 — CDMO Opportunities And Threats Report
Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

BIOPROCESSING WHITE PAPERS

Buffers And Process Liquids For Biopharmaceutical Production: Considerations For Scale-Up And Outsourcing
For small and midsize biopharmaceutical organizations, outsourcing buffer and process liquid preparation, quality testing, and storage could significantly streamline operations and reduce regulatory risk.

Time To Intensify: Taking mAb Manufacturing To The Next Level
8/19/2025

Explore how process intensification can revolutionize monoclonal antibody manufacturing to boost productivity, cut costs, and enhance sustainability with scalable strategies and real-world results.
Three Key Strategies To Guide Efficient And Effective Recall Management
2/18/2025

Discover how to successfully navigate recalls with a digital approach that helps achieve effective recall management, communication, and continuous improvement for brand integrity.
Unravelling The Complexities Of ADC Manufacturing
9/3/2025

Whether you're in the early stages of development or scaling up for commercialization, understanding ADC manufacturing challenges is essential for bringing life-saving therapies to patients worldwide.
Revolutionizing Manufacturing For Pharma And Biopharma
7/9/2024

Explore the evolution of Industry 4.0 in pharmaceutical manufacturing, the benefits and implications of Smart Factories, and the challenges along the road toward implementing a Smart Factory.
Optimizing Safety Measures For rAAV Therapies
10/11/2024

Explore common process-related impurities found in recombinant Adeno-Associated Virus (rAAV) vectors and the analytical testing methods used for these residuals.

More Bioprocessing White Papers

BIOPROCESSING APP NOTES & CASE STUDIES

More Bioprocessing App Notes & Case Studies

BIOPROCESS ONLINE CONTENT COLLECTIONS

This collection of articles digs into the industry’s growing focus on knowledge management as an indispensable facet of biomanufacturing and pharmaceutical development, exploring how it plays into risk management, quality, vendor relationships, and supply chain resilience.